Molecular classification is increasingly important in pediatric leukemia, where identifying specific gene fusions and other alterations can affect diagnosis, risk stratification, and treatment selection. But technical complexity, high costs, and long turnaround times can sometimes lead to patients outside specialist centers missing out on comprehensive leukemia diagnostics.
Now, the race is on to recover clinically important genomic variants at dramatically lower cost with a single, accessible assay combined with user-friendly bioinformatics.
Following his presentation at the AMP 2026 Meeting & Expo, we caught up with researcher Jeremy Wang to discuss the evolving landscape of pediatric leukemia testing.
What are the limitations of current molecular testing approaches for pediatric leukemia?
Modern molecular diagnostics for pediatric leukemia consists of a long series of time-consuming and often expensive tests – flow cytometry, karyotyping, FISH... any number of internal or send-out molecular tests. These require extensive infrastructure, equipment, and expertise even in well-resourced medical centers. As a result, they are often limited or absent in low-resource settings including low- and middle-income countries (LMICs), where most pediatric cancer patients are seen.
What prompted you to investigate long-read transcriptome sequencing as an alternative?
The main draw of long read, in particular nanopore sequencing, is the significantly lower equipment cost, required infrastructure, and expertise to operate it. We aimed to show that molecular data can be generated from a low-cost, portable sequencing platform that can be used to provide comprehensive multi-modal leukemia diagnostics at low sequencing depth and thereby low cost.
What are the practical advantages of your approach?
The sequencing platform itself is one advantage. On the Oxford Nanopore Technologies MinION sequencer (~$5,000 USD), we demonstrated that up to 12 samples can be multiplexed on one flow cell (~$1,000 USD) and provide practical diagnostic stratification, implying a consumables cost of around $100 USD per case.
The more compelling accessibility case, to me, is our development of efficient computational tools to enable bioinformatic analysis of these challenging data such that it can be performed and analyzed without dedicated bioinformatics personnel. The combined benefits of cost and ease-of-use can make this approach accessible in the diagnostic settings with limited infrastructure – in terms of both equipment and expertise.
How could more comprehensive molecular characterization change the diagnosis and treatment of children with leukemia?
Outcomes for pediatric leukemia are dramatically worse in LMICs compared to high-income countries, in part due to limited diagnostic capacity and specificity. This type of approach can help close that gap. If it can enable more precise, accurate molecular diagnostics, patients can be assigned to appropriate targeted or risk-stratified therapy – precision medicine – improving response rates to therapy and reducing treatment-related toxicity.
What further validation is needed before this approach could be adopted more widely?
We continue to validate this method, both at the University of North Carolina and with fabulous international collaborators around the world, who are working in centers where this technology would be most impactful. The next steps are to build out the data to show precise concordance – or, realistically, non-inferiority – of these results with standard of care diagnostics. Meanwhile, related methods, using low-cost sequencing platforms and multimodal genomic, transcriptomic, or epigenomic analysis with automated computational analysis, are being rapidly and widely brought into clinical practice.
